Cellectis Archives

News and Trends 15 Jul 2015

How Servier saved Cellectis, the French CAR-T Miracle

Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months away from bankruptcy, mainly because of the competing gene-editing technology CRISPR. How and why did Servier save them? Let’s find out. Cellectis was founded in 1999 in Paris and […]

July 15, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 25 Jun 2015

Video: Discover How CAR-T Therapies are Working

It’s becoming a habit for us to talk about CAR-T therapies. It’s basically the next wave of treatments against cancer and already promises to be the future blockbusters and growth drivers of the whole Biotech industry. Cellectis, a leading company in this field, just published a cool video about CAR-Ts. Of course, they’re describing more specifically their own therapy, […]

June 25, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 29 May 2015

Pfizer to Control Cellectis in a €1.5 Billion Deal?

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers. According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 26 Mar 2015

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Exactly one month ago, the article “Cellectis is preparing its IPO in the U.S” explained Cellectis prepared an IPO to be listed on the NASDAQ. Yesterday, the company announced the pricing of its initial public offering. Its goal is to raise €197M and up to €226.8M in case of allotment. A large amount of ressources […]

March 26, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 25 Feb 2015

Cellectis is preparing its IPO in the U.S

Cellectis is a company focused on developing immunotherapies based on gene edited engineered CAR-T cells. The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. With 15 years of expertise, Cellectis is already listed on the NYSE Alternext market (ticker: ALCLS) and now preparing its IPO to be listed on the […]

February 25, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 21 Jan 2015

Review: The CRISPR’s Therapeutical revolution

Six years ago, a new sophisticated prokaryotic defense system, was identified in the structure complex CRISPR-Cas9 (CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR associated nuclease). “Resistance is acquired by incorporating short stretches of invading DNA sequences in genomic CRISPR loci ” Brouns, S. J. J., et al. (2008). The CRISPR repeat sequence has […]

January 21, 2015 - 4 minutesmins - By Cédric Brock

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cellectis

How Servier saved Cellectis, the French CAR-T Miracle

Video: Discover How CAR-T Therapies are Working

Pfizer to Control Cellectis in a €1.5 Billion Deal?

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Cellectis is preparing its IPO in the U.S

Review: The CRISPR’s Therapeutical revolution

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!